bluebird bio (NASDAQ:BLUE) Stock Rating Reaffirmed by Wells Fargo & Co

bluebird bio (NASDAQ:BLUE)‘s stock had its “buy” rating reaffirmed by research analysts at Wells Fargo & Co in a report released on Thursday, AnalystRatings.com reports.

A number of other research analysts have also weighed in on BLUE. BidaskClub raised bluebird bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 21st. Morgan Stanley reduced their price target on bluebird bio from $100.00 to $92.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. JPMorgan Chase & Co. reissued a “buy” rating on shares of bluebird bio in a research note on Sunday, January 19th. Stifel Nicolaus reduced their price target on bluebird bio from $96.00 to $94.00 and set a “hold” rating on the stock in a research note on Wednesday, February 19th. Finally, Oppenheimer reduced their price target on bluebird bio from to in a research note on Thursday, February 20th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $128.27.

Shares of bluebird bio stock traded down $0.72 during trading hours on Thursday, reaching $46.60. 1,003,238 shares of the company’s stock were exchanged, compared to its average volume of 1,067,995. bluebird bio has a 52-week low of $38.95 and a 52-week high of $163.43. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -3.26 and a beta of 2.36. The company has a fifty day moving average of $70.24 and a 200-day moving average of $83.66. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.13.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Tuesday, February 18th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.79) by ($0.25). bluebird bio had a negative return on equity of 51.23% and a negative net margin of 1,767.49%. The business had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $8.23 million. During the same period in the prior year, the company earned ($2.72) EPS. The company’s revenue for the quarter was down 47.9% compared to the same quarter last year. On average, equities research analysts anticipate that bluebird bio will post -15.64 earnings per share for the current fiscal year.

In related news, insider Alison Cecily Finger sold 517 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $84.96, for a total value of $43,924.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Nick Leschly sold 10,163 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $89.97, for a total value of $914,365.11. Following the completion of the sale, the chief executive officer now owns 56,712 shares of the company’s stock, valued at $5,102,378.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,784 shares of company stock valued at $1,149,985. 3.00% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC acquired a new stake in shares of bluebird bio during the fourth quarter valued at about $47,000. Whittier Trust Co. grew its stake in bluebird bio by 36.5% in the fourth quarter. Whittier Trust Co. now owns 542 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 145 shares in the last quarter. Rational Advisors LLC grew its stake in bluebird bio by 80.6% in the fourth quarter. Rational Advisors LLC now owns 708 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 316 shares in the last quarter. Samalin Investment Counsel LLC acquired a new position in bluebird bio in the fourth quarter worth about $100,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in bluebird bio in the fourth quarter worth about $106,000.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

See Also: Call Option

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.